Semaglutide
Aliases: Ozempic · Wegovy · Rybelsus
Last verified: 2026-09-23
The short version
Semaglutidee is the reference point of modern medical science: the STEP program (4,000+ participants) showed ~15% average body weight loss at weekly dosing, with partial persistence at one year. The SUSTAIN program confirmed cardiovascular protection in diabetics (MACE -26%). But it is not a 'vitamin': nausea is very common, pancreatitis and gallbladder complications occur rarely, and muscle mass loss during rapid weight loss is a real problem requiring a strategic approach. This is a drug that requires a physician.
Identity & type
- Molecular type
- analog
- Sequence / structure
- 31-mer GLP-1 analog, C18 diacid bočni lanac
- Molecular weight
- ~4114 Da
- Origin
- GLP-1 analog with an extended half-life (~7 days), enabling weekly dosing; basis of Ozempic, Wegovy, Rybelsus.
Mechanism of action
GLP-1R agonist → enhanced glucose-dependent insulin secretion, slowed gastric emptying, central appetite suppression.
Dosing & routes
Official / clinical context
Approved drug — indications, dosing and warnings are defined by the official label. Wegovy: titration to 2.4 mg SC weekly; Ozempic 0.5–2 mg; Rybelsus 3–14 mg orally daily.
Regulator-approved labeling and published study designs — never a recommendation.
Community-reported practice
Wegovy: titration to 2.4 mg SC weekly; Ozempic 0.5–2 mg; Rybelsus 3–14 mg orally daily. Ozempic/Wegovy: pronounced satiety, silenced "food noise", 10–15% weight loss over a year; nausea most common in week one. The community also notes reduced alcohol craving in some users.
Unverified self-reports. Not medical advice. Not endorsement.
Expected effects (community)
Ozempic/Wegovy: pronounced satiety, silenced "food noise", 10–15% weight loss over a year; nausea most common in week one. The community also notes reduced alcohol craving in some users.
Protocol — official vs community
Official / label
Wegovy (obesity): 2.4 mg SC once weekly. Ozempic (T2D): 0.5–2 mg weekly. Rybelsus: 3–14 mg oral daily.
- 01Weeks 1–4: 0.25 mg weekly
- 02Weeks 5–8: 0.5 mg weekly
- 03Weeks 9–12: 1 mg weekly
- 04Weeks 13–16: 1.7 mg weekly
- 05Week 17+: 2.4 mg maintenance
Duration: Chronic. Discontinuation leads to weight regain in most patients within a year.
Slow titration over ≥16 weeks is what makes the GI side-effect load survivable. Escalate only if the previous step is tolerated.
Community (anecdotal)
Mirrors label titration. Gray-market users typically start at 0.25–0.5 mg weekly regardless of stated vial contents.
- Cycle:
- Continuous — not cycled.
- Break:
- None by design; 'GLP-1 holidays' are not evidence-based and regain follows.
Community practice differs from the label mainly in sourcing and in under-dosing during shortages — not in structure.
Human evidence
Among the most robust evidence in medicine: STEP 1–8, SUSTAIN 1–7, SELECT (17,000+ participants, CV prevention in obese non-diabetics).
Preclinical evidence
The preclinical phase was completed and submitted to regulators as part of registration; pharmacology and toxicology details are part of the official label.
Known risks
- Nausea, vomiting, diarrhea (~40% in first months)characterized
- Gallstones and rarely pancreatitischaracterized
- Muscle mass loss with large weight reductioncharacterized
- Insufficient data in pregnancy; contraindicatedcharacterized
Teal: characterized in clinical/labeling contexts. Amber: theoretical or reported outside controlled settings.
Unknowns & evidence gaps
- Full duration of use (decades) and rare-event risk
- Optimal muscle-preservation strategy
Frequently asked questions
References
- Wilding J.P.H. et al., STEP 1 (N Engl J Med, 2021)
- Marso S.P. et al., SUSTAIN-6 (N Engl J Med, 2016)
- Lincoff A.M. et al., SELECT (N Engl J Med, 2023)
- Wegovy/Ozempic — FDA labeli